Today, our focus is to develop and provide a broader range of high-quality products that will help fill gaps in women’s health. Our experience in drug development, clinical trial research, and regulatory affairs makes us uniquely positioned to address the high cost of medicines in the U.S.
Our commitment to addressing unmet needs for medicines also extends to women globally. Our team works with regulatory agencies in Africa, Asia, and Central America to make our hormonal IUD available under the brand name, AVIBELATM. We make AVIBELA available at a low cost through global procurement agencies, Ministries of Health and through relationships with global non-governmental organizations (NGOs).
Conducting clinical trials to demonstrate safety and efficacy of drugs and devices
Navigating the regulatory process to ensure medical products meet high standards for approval
Medicines360 conducted the United States’ largest and most diverse Phase 3 clinical trial ever on a hormonal IUD. To date, in collaboration with our commercial partner, we have made our hormonal IUD available to more than 1.2 million women throughout the United States. Our work in the public sector has also served approximately 2,500 publicly funded clinics throughout the U.S., saving the public healthcare system an estimated $90 million.
Despite the increased number of women who have been able to obtain an affordable contraceptive option, there is more to be done to truly realize equitable access to the medicines that women need.
Increased philanthropic investment to offset the high cost of product development, research, and regulatory fees can allow the nonprofit pharmaceutical industry to fill gaps and ensure equitable access to medicines.
Advancing a New "Nonprofit Pharma" Model
Nonprofit Pharma Model
Our Strategic Priorities
Complex problems require multi-faceted, long-term solutions. As a social enterprise, we are driven to help make equitable access to medicines a reality for women. Our organization has developed momentum to address one of the most pressing issues that plague our current system – the high cost of drugs that prohibits access for many women. We will continue engaging with stakeholders and philanthropic donors to bring new and expanded resources to our work in product development, policy advocacy, and public sector engagement.
Since our founding in 2009, we have learned critical lessons that have informed our priorities for the next chapter in our pursuit of equitable access.
The Pathway to Impact
Closing gaps in equitable access is a significant challenge and cannot be solved by any one organization alone. It is only through working with others that we can achieve meaningful change. As such, we are proud of the relationships we have formed with organizations to develop and distribute products in the U.S. and globally. These collaborations reflect diverse, yet complementary organizations that collectively contribute to support and uplift women.
Sign up for our quarterly e-newsletter focused on improving women’s health.
We give you many choices regarding our use and disclosure of your Personal Information for marketing purposes. You may opt out from:
- Receiving marketing-related emails from us: If you no longer want to receive marketing-related emails from us on a going-forward basis, you may opt out of receiving these marketing-related emails by following the instructions included in email communications from us, or contact us at: email@example.com.
- Our sharing of your Personal Information with affiliates for their marketing purposes: If you would prefer that we do not share your Personal Information on a going-forward basis with our affiliates for their marketing purposes, you may opt out of this sharing by notifying us sending us a written statement to: Medicines360 Website, 49 Stevenson St | Suite 1100 | San Francisco, CA 94105 USA, by following the instructions included in email communication you received from us, or by contacting us at: firstname.lastname@example.org.
- Kaiser Family Foundation. Women’s Health Insurance Coverage. Accessed June 2022
- The Lancet. Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970–2019: a systematic analysis for the Global Burden of Disease Study 2019. Accessed August 2022